BioAtla Investor Conference Presentation Deck

Selective and targeted CAB technology widens therapeutic index, thus has the potential to enhance clinical outcomes in multiple tumor types المدم BioAtla discovered that acidic pH at the cancer cell surface unveils binding sites that are shielded at normal pH of healthy cells BioAtla invented CAB technology, creating antibodies that bind only to these unveiled sites on cancer cells CAB binding region is not masked or caged and thus different from prodrugs that require irreversible enzymatic cleavage to become activated CAB antibodies have the potential for increased efficacy with improved safety relative to traditional antibodies bicatla Alkaline Healthy Cell Membrane Glycocalyx Basic pH HEALTHY CELL FAVOR Intracellular Mildly Acidic pH No CAB Binding H+ H H+ CAMERASER Acidic Cancer Cell Membrane CANCER CELL Intracellular Mildly Basic pH. CAB Binding H+ H+ H* H+ H Glycocalyx Acidic pH H+ H+ CUTORI Chang, H.W., Frey, G., Liu, H., Xing, C., Steinman, L, Boyle, B.J., & Short, J.M. (2021) PNAS 118(9): 1-10, Suppl. 1-19. BioAtla Overview | Company Confidential 4

View entire presentation